Accordingly, genetic interference of the circuit through ablation of either tuft cells or ILC2s, or therapeutic suppression of IL13 or IL25 signaling, confers profound therapeutic benefits at both earliest stages (i.e. gastric metaplasia) as well as later stages (i.e. gastric adenomas and adenocarcinomas) along the tumor trajectory. This evidence concerns the gene IL25 and neoplasm.